Olverembatinib
Childhood Leukemia, Acute Lymphoblastic
Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
70 Active assets in the Childhood Leukemia, Acute Lymphoblastic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 3 | BBB |
MERCAPTOPURINE ANHYDROUS Children's Oncology Group | Phase 3 | BBB |
METHOTREXATE Children's Oncology Group | Phase 3 | BBB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 3 | BBB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Olverembatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
66 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →